Extensive cardiovascular disease is the major cause of morbidity and mortality in patients with angina pectoris. Therefore, optimal atheroma management is a key strategy for preventing subsequent cardiovascular events. Prior intravascular ultrasound (IVUS) trials have reported a slowing of coronary atheroma progression or regression with some medicines, such as statins or pioglitazone, suggesting the possibility for pharmacological interventions (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . By contrast, chronic activation of the renin-angiotensin system is a well-established contributor to the development and progression of atherosclerosis (14) . Although recent trials, the similarities of effects on preventing myocardial infarction (MI) between ARB and angiotensinconverting enzyme (ACE) inhibitors have also been reported (20) . However, the potential advantage beyond antihypertensive efficacy for plaque modification has not been well-clarified in atherosclerotic human coronary arteries. Thus, we investigated the impact of administration of olmesartan, an ARB, on the progression of coronary atherosclerosis as assessed by serial IVUS interrogation.
Methods
Patients and study design. The OLIVUS (Impact of OLmesartan on the progression of coronary atherosclerosis: evaluation by IntraVascular UltraSound) trial is a prospective, randomized, multicenter trial. The study protocol was approved by all participating institutional review boards, and all patients provided written informed consent. Patients with clinically stable angina pectoris and hypertension scheduled for percutaneous coronary intervention (PCI) were enrolled. After PCI for their culprit lesions, IVUS was performed over 40 mm in their nonculprit vessels-defined as without angiographically documented coronary stenosis Ͻ50%-to determine atheroma volume at baseline.
Patients with complicated lesions, such as excessive tortuosity or calcified lesions, unable to cross with IVUS, chronic renal failure (serum creatinine Ͼ1.5), unstable patients, recent MI within 4 weeks, poor ejection fraction Ͻ25%, and patients already taking ACE inhibitors or ARBs were excluded from the trial. Patients were randomized to control or olmesartan 10 to 40 mg titrated to maximally tolerated dose by 8 weeks. In addition, patients were treated with a combination of beta-blockers, calcium channel blockers, diuretics, nitrates, glycemic control agents, and/or statins per physician's guidance. After 12 to 16 months, IVUS of the originally examined coronary artery was performed during the routine follow-up angiogram. Our primary end point of interest was the impact of administration of olmesartan on coronary atherosclerotic changes evaluated by volumetric IVUS. Other outcomes included adverse events, such as cardiovascular death, nonfatal MI, nonfatal stroke, noncardiovascular death, hospital stay for unstable angina, hospital stay for chronic heart failure, or deterioration of chronic renal failure. IVUS. The IVUS studies were performed with a commercially available imaging system with a 40-MHz mechanical transducer ultrasound catheter (Boston Scientific Corporation, Natick, Massachusetts). After intracoronary nitroglycerin administration, the imaging catheter was advanced over the coronary wire to the mid-to-distal vessel under fluoroscopic guidance. Cine runs, before and during contrast injection, were performed to define the position of the catheter distal to an identifiable side branch. With automated pullback (0.5 mm/s), digital ultrasound images were obtained and recorded on DVDs for subsequent off-line IVUS analysis. The DVDs containing the IVUS pullbacks were analyzed in a blinded fashion by the IVUS core laboratory in the Sakakibara Heart Institute of Okayama. After image acquisition, 3-dimensional volumetric analysis was performed with Simpson's method by dedicated software (EchoPlaque, Indec Systems, Mountain View, California). The operator selected a distal fiduciary site, usually a branch site, as the beginning point for analysis. Subsequently, every 30th frame image was analyzed, generating a series of cross-sections spaced exactly 0.5 mm apart. The final crosssection analyzed was obtained at a proximal fiduciary site. Corresponding coronary segments over the 40 mm in the non-PCI-culprit vessels were selected, and IVUS measurements included vessel, lumen, and total atheroma volume (TAV). To standardize for vessel size, percent atheroma volume (PAV)-defined as atheroma volume divided by vessel volume-was also calculated. The serial progression rate of atherosclerosis was compared with change in TAV and change in PAV, measured by (follow-up TAV Ϫ baseline TAV)/baseline TAV ϫ 100 and (follow-up PAV Ϫ baseline PAV)/baseline PAV ϫ 100, respectively. A representative case is presented in Figure 1 . Intraobserver variability has been previously reported (21) . Statistical methods. Analyses were performed with SPSS version 11 software (SPSS, Inc., Chicago, Illinois). Laboratory and ultrasound parameters are described with frequencies, whereas continuous variables are reported as mean, median (with 95% confidence intervals [CIs]), and SDs. Whether data were normally distributed was examined by the Kolmogrov-Smirnov test. If data were not normally distributed, testing for significant differences of each parameter between baseline and follow-up was performed with the Mann-Whitney U test. Serial atheroma and PAV changes were compared with a 2-tailed, paired Student t test. Linear regression was applied to determine correlations between blood pressure reduction and atheroma progression rate. Multiple linear regression and logistic regression analysis were applied to determine the independent predictors of coronary atheroma changes.
A p value of 0.05 was considered to be statistically significant. In the protocol, the assumptions used for power calculations required a sample size of 98 patients/treatment group to provide 80% power (assuming an SD of 12.5%) to detect a 5.0% difference in the primary efficacy parameter, change in PAV, with a 5% type I error rate for a 2-sided test. With an anticipated dropout rate of approximately 20%, enrollment of 123 patients/treatment group (total 246 randomized patients) was specified to provide an adequate number of evaluable IVUS patients. Hirohata et al. March 9, 2010:976-82 ARBs and the Progression of CAD
Results
Between February 2006 and August 2007, 247 patients with stable angina pectoris undergoing PCI were enrolled in this trial. During follow-up, 15 patients in the control group and 17 patients in the olmesartan group dropped out from the trial because of adverse events, laboratory abnormality, or withdrawal of consent. Therefore, follow-up IVUS (average 388 Ϯ 54 days) was performed in 215 participants; however, 4 cases in the control group and 6 cases in the olmesartan group were excluded from analysis due to poor IVUS image quality, such as nonuniform rotational distortion, inconsistent pullback, or large axial movement of the IVUS catheter.
As a result, a total of 205 patients completed the serial IVUS analysis, and average analyzed lengths were 42.6 mm. The numbers of patients screened and randomized and reasons for dropping out are reported in Figure 2 . Vital status was ascertained in 230 patients (93.1%) at the end of the study. Of the 109 (86.5%) patients taking olmesartan at the end of the study, 105 (83.3%) were receiving the full dose (20 to 40 mg), with only 4 (3.2%) receiving a reduced dose. Patient characteristics and blood pressure changes. Patient characteristics and medications at baseline are summarized in Tables 1 and 2 . All data are identical between the control and olmesartan groups. At the time of enrollment, approximately 30% to 40% of patients were already being treated with antihypertensive agents, except ACE inhibitor or ARB and/or statins. Serial changes in blood pressure are presented in Table 3 . In this trial, control of blood pressure was at the physician's discretion except for administration of olmesartan. Although significant improvement of blood pressure was observed in both groups, there was no significant difference between the control and olmesartan groups. Major cardiovascular events. Adjudicated major cardiovascular events are summarized in Table 4 . There was no difference in terms of cardiovascular death, nonfatal MI or nonfatal stroke, coronary revascularization, hospital stay for congestive heart failure, or deterioration for chronic renal failure between the 2 groups. Volumetric IVUS analysis. Table 5 summarizes the volumetric IVUS results changes in IVUS parameters from baseline to follow-up. Significant development of atheroma volume and PAV were found in the control group between baseline and follow-up (p Ͻ 0.05). Except for PAV at baseline, there were no differences in any other IVUS parameter measured between the control and olmesartan groups. Table 6 illustrates the results for the nominal and percentage change in atheroma volume, which is the primary efficacy parameter. In a comparison of the 2 regimens, the progression rate was significantly lower in the olmesartan group (p ϭ 0.016 for nominal change in TAV, and p ϭ 0.038 for PAV change). The nominal changes in atheroma volume and PAV were positive in the control group (7.1 mm 3 and 1.1%, respectively), indicating net progression (p ϭ 0.009 and p ϭ 0.039 compared with baseline, respectively). In the olmesartan group, the nominal change in atheroma volume and PAV were negative (Ϫ2.6 mm 3 and Ϫ0.1%, respectively), showing no disease progression (p ϭ 0.34 and p ϭ 0.89 compared with baseline, respectively). However, in this trial, there was no statistically significant correlation between blood pressure reduction and atheroma progression rate. Results of a multiple linear regression test-which is defined as percentage change of atheroma volume as a dependent variable-are summarized in Table 7 , and results of logistic regression test for increased atheroma volume during follow-up periods are in Figure 3 . Both results identified olmesartan administration as 1 of the factors that decreased atheroma volume. In the diabetic subanalysis, there was significant difference in PAV changes when compared with baseline hemoglobin A1c Ͻ6.5% and Ն6.5% groups (Ϫ0.40% vs. 5.1%, p ϭ 0.01). However, in the statin subanalysis, there was no difference between the 2 groups. By contrast, there was a difference in PAV change when compared with baseline low-density lipoprotein cholesterol Ͻ120 and Ն120 mg/dl groups (0.2% vs. 4.1%, p ϭ 0.06). Hirohata et al. March 9, 2010:976-82 ARBs and the Progression of CAD
Baseline Medication

Discussion
In the present study, significant effect for lower rate of coronary atheroma progression was observed in patients receiving olmesartan, an ARB, compared with the control group during the 14-month follow-up period. Currently, ARBs are widely used for the treatment of hypertension. They also have beneficial effects on hypertension-related cardiovascular end organ damage, possibly due to reduction of oxidative stress and inflammation (14,16 -18,22,23) . Among the several ARBs available in the clinical setting, olmesartan is thought to have a significantly stronger blood pressure-lowering effect than other ARBs with their respective starting doses (19) . In addition, previous clinical studies reported the potential decrease of atheromatous plaque burden in the human artery after administration of olmesartan or ARB compared with the control group (24, 25) . Thus, it might be not surprising that olmesartan showed coronary plaque regression in this trial. However, the underlying mechanisms as well as the clinical impact of ARB remain a matter of ongoing debate. According to the results of a recent trial, the similarity of effects on reducing MI between ARB and ACE inhibitors should help to dispel concerns that ARB might not reduce MI (20) . Our study data might show the corroborating efficacy for these medicines in terms of preventing the progression of atherosclerosis.
In the present trial, there was no significant effect on the adjudicated major cardiovascular events during the 14-month follow-up period. The primary end point of this trial was change in coronary atheroma volume, assessed by serial IVUS; therefore, we enrolled only a small number of patients with stable angina. Furthermore, it has been reported that there is a delay of 6 to 12 months before the benefits of an ARB emerge and that it might take several years of treatment for the full benefits to manifest (20) . Longer-term follow-up and a larger study might be required to confirm the long-term results.
There was no significant difference in terms of changes of blood pressure (26 -29) . In this trial, control of blood pressure was left to the physician's discretion except for administration of ARBs and ACE inhibitors; therefore, an incremental dose of other antihypertensive agents, such as beta-blockers, calcium channel blockers, and/or diuretics, might have contributed to the similarities in blood pressure control between the 2 groups.
Previous studies with arbitrary short segment analyses have described progression or regression with respect to atheroma volume changes over time in coronary arteries. 
Changes in IVUS Parameters
From Baseline to Follow-Up Table 5 . However, plaque deposition is a continuous variable; thus, arbitrary short segment analyses might not necessarily indicate the degree or extent of atherosclerosis in the entire coronary tree. In the present study, volumetric IVUS analyses were completed exclusively in entire vessels; therefore, these IVUS parameters represent atheroma progression of measured coronary arteries. According to our serial IVUS observations, progression/regression atheroma burden through administration of olmesartan seems to be associated with vessel remodeling. These findings are concurrent with previous studies using statins and might suggest a possible similar atheroma reductive process for ARB (30 -32) .
Results of a Multiple Linear Regression Test
In the present study, multivariate analysis identified olmesartan administration as 1 of the factors that decreased atheroma volume. However, a high proportion of patients in our study were already being treated with lipid-lowering agents, antiplatelet agents, and/or other blood-pressurelowering drugs, except ARBs or ACE inhibitors, which might have minimized the differences in plaque changes seen between the 2 randomized groups, compared with those seen in previous trials. There were several studies assessing temporal changes in percent plaque volume with IVUS (1-9,33,34). Compared with previous studies, results of the present study seem to show convincing serial changes of coronary atheroma volume. In the present study, the differences in IVUS parameters were relatively small-perhaps associated with this study population having received optimized lipid-lowering therapy, beta-blockers, and antiplatelet drugs-compared with subjects in previous clinical trials. Nevertheless, the olmesartan group had a substantially lower progression rate than would have been predicted for the low-density lipoprotein cholesterol level achieved. In addition, in the present trial, there was no statistically significant correlation between blood pressure reduction and atheroma progression rate (27, 28) . This might suggest the potential manifold action of olmesartan, apart from the antihypertensive effect, that might be beneficial, such as activity leading to atheroma stabilization and reduction. We believe this is the first clinical trial that shows potential reduced progression of coronary atherosclerosis with an ARB. Our study data might add another striking benefit to the ever-growing list of positive outcomes associated with olmesartan administration. Study limitations. First, a small number of patients with stable angina pectoris were enrolled; therefore, some selection bias might exist. Second, the IVUS results showed relatively larger SDs; however, these are not unusual for this kind of study. In addition, development of coronary atheroma might not be directly associated with the incidence of a cardiovascular event; therefore, qualitative plaque assessment, such as virtual histology-IVUS or optical coherence tomography, and longerterm follow-up might also be required. In addition, a high proportion of patients in our study were already being treated with optimal lipid-lowering therapy; therefore, it might be difficult to show an effect in addition to that treatment.
Conclusions
These observations suggest a positive role in a potentially lower rate of coronary atheroma progression through the administration of olmesartan, an ARB, for patients with stable angina pectoris.
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